8.11
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with dif…
For drugs that follow nonlinear pharmacokinetics, the absorption, distribution, and elimination processes may potentially saturate.
A saturable pathway can lead to dose-dependent changes in the bioavailability of a drug.
The extent of bioavailability is generally estimated using 
, which can be affected by saturation-limited absorption in the gastrointestinal tract, or concentration-dependent AUC, which can be affected by the enzymes involved in drug elimination.
Nonlinear pharmacokinetics can also stem from drug-protein binding. Protein-bound drugs exhibit longer elimination half-lives and slower elimination rates than free drugs.
High levels of protein binding result in reduced free drug available for glomerular filtration during renal excretion.
The concentration of the free drug, Cf, can be determined using an equation.
For protein-bound drugs, the free drug concentration is invariably lower than the total drug concentration.
Valproic acid is an example of a drug that shows nonlinear pharmacokinetics, partially due to nonlinear protein binding.
View the full transcript and gain access to JoVE Core videos
Q1: What causes bioavailability to change with different drug doses in nonlinear pharmacokinetics?
In nonlinear pharmacokinetics, saturable pathways cause dose-dependent changes in bioavailability. As drug concentration increases, the absorption pathway becomes saturated, decreasing the absorption rate and resulting in lower bioavailability than expected at higher doses. This saturation limits how much drug reaches systemic circulation.
Q2: How does protein binding affect drug elimination rates?
Protein-bound drugs exhibit longer elimination half-lives and slower elimination rates than free drugs. Only the unbound drug fraction is available for elimination through renal excretion or metabolism, while the protein-bound portion remains in circulation longer. High protein binding reduces the free drug concentration available for glomerular filtration.
Q3: Why is free drug concentration always lower than total drug concentration?
Free drug concentration is lower than total drug concentration because most of the drug binds to plasma proteins like albumin. The protein-bound portion remains sequestered in circulation and unavailable for therapeutic action or elimination. Only the unbound fraction represents the pharmacologically active drug available for distribution and clearance.
Q4: What parameter do pharmacologists use to quantify bioavailability in nonlinear pharmacokinetics?
Pharmacologists use AUC (area under the plasma concentration-time curve from time zero to infinity) to quantify bioavailability. However, AUC can be influenced by saturation-limited absorption in the gastrointestinal tract or concentration-dependent changes affected by drug-metabolizing enzymes, complicating bioavailability estimation for nonlinear drugs.
Q5: How does saturation of absorption pathways affect drug bioavailability at higher doses?
When absorption pathways saturate at higher doses, the rate of drug absorption decreases despite increased drug concentration. This saturation means the gastrointestinal tract cannot absorb proportionally more drug, resulting in lower bioavailability than predicted by linear kinetics. The saturable pathway becomes a rate-limiting step in drug absorption.
Q6: What is an example of a drug exhibiting nonlinear protein binding?
Valproic acid demonstrates nonlinear pharmacokinetics partially due to nonlinear protein binding. Its binding to plasma proteins is not linearly related to its concentration, contributing to dose-dependent bioavailability and variable elimination rates. This nonlinearity exemplifies how protein-drug interactions complicate pharmacokinetic behavior.
Q7: How do saturable pathways and protein binding interact to create nonlinear pharmacokinetics?
Saturable pathways limit absorption and elimination capacity, while protein binding sequesters drug in circulation and reduces free drug availability. Together, these factors cause dose-dependent changes in bioavailability and elimination rates. Understanding parameters affecting nonlinear elimination helps optimize dosing regimens and predict drug behavior across different concentrations.